{"id":390737,"date":"2018-02-26T00:00:00","date_gmt":"2018-02-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0033-2018-biopharma-ankylosing-spondylitis-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-23T11:40:06","modified_gmt":"2026-04-23T11:40:06","slug":"algoim0033-2018-biopharma-ankylosing-spondylitis-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0033-2018-biopharma-ankylosing-spondylitis-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Ankylosing Spondylitis | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p><abbr data-original-title=\"ankylosing spondylitis\" title=\"\">AS<\/abbr>\u00a0is a chronic inflammatory disease belonging to the group of spondyloarthritides, involving primarily the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Diagnosis can be difficult, and left untreated\u00a0<abbr data-original-title=\"ankylosing spondylitis\" title=\"\">AS<\/abbr>\u00a0can result in structural damage and disability. The key treatment goals for\u00a0<abbr data-original-title=\"ankylosing spondylitis\" title=\"\">AS<\/abbr>\u00a0include improving signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage.\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors have demonstrated efficacy in reducing disease activity in\u00a0<abbr data-original-title=\"ankylosing spondylitis\" title=\"\">AS<\/abbr>, and all approved agents in this class are perceived as highly effective options for patients who require more potent therapies beyond first-line\u00a0<abbr data-original-title=\"nonsteroidal anti-inflammatory drug\" title=\"\">NSAID<\/abbr>s. The\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitor Cosentyx offers an alternative mechanism of action as the only approved non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>\u00a0biologic therapy for\u00a0<abbr data-original-title=\"ankylosing spondylitis\" title=\"\">AS<\/abbr>.t<\/p>\n","protected":false},"template":"","class_list":["post-390737","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390737\/revisions"}],"predecessor-version":[{"id":393861,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390737\/revisions\/393861"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}